Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
about
Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study[Isoniazid-induced hepatic failure. Report of a case].Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.Hepatic safety of antibiotics used in primary careSuccessful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis.Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two dosesNAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapyA Pilot Trial of Jawarish Amla as Adjuvant to Anti-Tubercular Treatment Drugs for Control of Adverse Reactions in DOTS Regime in Pulmonary TB.Pharmacogenetics of drug-induced liver injury.Detection and management of latent tuberculosis in liver transplant patients.Future of pharmacogenetics-based therapy for tuberculosis.Isoniazid: A Review of Characteristics, Properties and Analytical Methods.Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors.A comparison between two strategies for monitoring hepatic function during antituberculous therapy.Antioxidant status and GST gene polymorphisms in antitubercular treatment-induced hepatotoxicity patients.Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity.Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation.Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin.Evaluation of the physicians' approach to the diagnosis and treatment of patients with antituberculosis drug-induced hepatotoxicity.Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid.
P2860
Q28488142-B8BB70FB-3494-47AD-8194-D37FDDC7864EQ31431950-79C2B11D-43DB-4B0F-A9ED-7ACECB17B559Q33889576-3B9E3E06-3CCE-4A4E-B854-9ABAFB6B225AQ35037383-89F9A07D-1AF4-404D-914F-252A8FB22899Q35871161-08204584-5E04-41F8-885B-9FC57A45738EQ36364005-E36F1204-2C5C-48E9-9E13-D855543D94F7Q36535942-0508226A-DD08-4D78-B573-755FD497CA8CQ36809405-CD532C1C-9E8C-4C28-8822-56E8C5AA7D3BQ37003603-CEF5481C-BF27-4016-B319-838A1DF44496Q37770487-CD9EB127-5870-4111-890D-763F4B7E5523Q37850764-56CE8D48-1457-473F-AADD-934132CC5701Q38209573-BCBC9744-5A62-4F68-96E4-DF8BADD93B2CQ39083469-C10CB0FE-0097-41EB-967B-99C3BDD29FC9Q39683838-17696CED-BB46-4E4B-9A40-6B5EA35B4768Q40013706-46B8CF15-4BB7-4F83-9AE9-BBEE898AA9D8Q40706938-B4A14C53-1C23-4511-80CF-AD1A9A610EE5Q43145481-09763B2D-9CB4-48F2-882F-0532B857A2B6Q43275327-68254FA9-0786-4C02-A353-2472CCB2C8A6Q43762376-1C9A3F11-17F6-4E7F-B562-D4B1168CC158Q44646549-BA6E0CE1-C597-4313-802B-B7DA13713B82Q45866393-3AEDD1AF-F3CA-4BDE-BCBA-2EE3B0C37CFFQ53743200-A0F84260-25B1-4DCC-A06B-3E5BF554150E
P2860
Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
@en
type
label
Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
@en
prefLabel
Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
@en
P2093
P1433
P1476
Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
@en
P2093
P304
P356
10.2165/00002018-199615060-00004
P577
1996-12-01T00:00:00Z
P6179
1023649851